[EN] HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF [FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE, ET COMPOSITIONS ET MÉTHODES D'UTILISATION DE CEUX-CI
[EN] HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF [FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE, ET COMPOSITIONS ET MÉTHODES D'UTILISATION DE CEUX-CI
Mechanism and regioselectivity of the anionic oxidative rearrangement of 1,3-diketones towards all-carbon quaternary carboxylates
作者:Emma Bratt、Samuel Suárez-Pantiga、Magnus J. Johansson、Abraham Mendoza
DOI:10.1039/c9cc03331a
日期:——
The oxidative rearrangement of 1,3-diketones is an underexplored alternative to enolate chemistry in the synthesis of all-carbon quaternary carboxylates. The mechanistic investigation of this reaction has resulted in a mild base mediated protocol, whose regioselectivity has been studied in challenging acyclic substrates.
of 1,n-dicarbonyl compounds through the homolytic C–C bond cleavage of unstrained carbocyclic and heterocyclic ring systems. This method exhibits a lot of synthetic advantages including mild conditions, simple operation, and convenience of amplification. Mechanistic studies support the generation of peroxy radical species via oxygen capture followed by radical fragmentation.
Electrochemical Decarboxylative Elimination of Carboxylic Acids to Alkenes
作者:Jiage Yu、Teng Liu、Wanhao Sun、Yunfei Zhang
DOI:10.1021/acs.orglett.3c02997
日期:2023.11.3
An electrochemical strategy for the decarboxylative elimination of carboxylic acids to alkenes at room temperature has been developed. This mild and oxidant-free method provides a green alternative to traditional thermal decarboxylation reactions. Structurally diverse aliphatic carboxylic acids, including biologically active drugs, underwent smooth conversion to the corresponding alkenes in good to
Histone deacetylase inhibitors and compositions and methods of use thereof
申请人:CHDI Foundation, Inc.
公开号:US10065948B2
公开(公告)日:2018-09-04
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.
本文提供了某些式 I 的组蛋白去乙酰化酶(HDAC)抑制剂或其药学上可接受的盐、其组合物及其使用方法。由 HDAC 介导的病症或紊乱包括神经退行性病理学。因此,还提供了一种在需要治疗的受试者中治疗由HDAC介导的神经退行性病理的方法,包括向受试者施用治疗有效量的至少一种本文所述的化合物或其药学上可接受的盐。
The Decarboxylation of 1-Phenylcycloparaffin-1-carboxylic Acids